VBV. A. Biryukov

V. A. Biryukov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


V. A. Biryukov has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Andrei Dmitrievich Kaprin

    National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia

    9 shared publications
  • Oleg B. Karyakin

    A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

    9 shared publications
  • Sergey Anatolyevich Ivanov

    A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

    8 shared publications
  • E. O. Shchukina

    A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

    4 shared publications
  • K. S. Makarova

    A.F. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center, Ministry of Health of Russia

    4 shared publications
  • O. G. Lepilina

    Медицинский радиологический научный центр им. А.Ф. Цыба – филиал федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации (МРНЦ им. А.Ф. Цыба – филиал ФГБУ «НМИЦ радиологии» Минздрава России)

    4 shared publications

Latest Publications

  • Morphological changes after radiation therapy for prostate cancer

    by N. A. Gorban, K. A. Ruchina, I. E. Ingel, A. G. Kudaybergenova, V. A. Biryukov

    This review summarizes data from recent decades on morphological changes in prostate tissue following radiation therapy, including external beam radiation and brachytherapy. Structural, cytological and immunohistochemical changes in both normal tissue and adenocarcinoma are discussed, along with diagnostic pitfalls in the assessment of residual tumor and the interpretation of Gleason score after irradiation. Particular attention is given to the prognostic value of post-treatment biopsy, definition of biochemical recurrence, and prostate-specific antigen bounce phenomenon after brachytherapy.

  • Open Access

    Cognizance and adherence to outpatient treatment in patients with prostate cancer after local treatment: multicenter study

    by Vladimir M. Perepukhov, K. M. Nyushko, B. Ya. Alekseev, I. M. Shevchuk, V. P. Aleshin, N. D. Movchan, O. A. Mailyan, R. L. Sugaipov, F. Sh. Mangutov, V. A. Biryukov, et al.

    Background. Prostate cancer is the most common cancer among men in Russia. Despite the successes of local treatment, the risk of biochemical recurrence (BR) persists and requires long-term monitoring of prostate-specific antigen (PSA). Patient compliance is a crucial factor of timely recurrence diagnosis. Aim. To evaluate cognizance and adherence to outpatient treatment in patients with local and locally advanced prostate cancer after local treatment in Russia. Materials and methods. Two-stage study was performed: survey of 22 oncologists from 18 centers and telephone survey of 2046 patients from 10 oncological centers who received local treatment in 2022. Original questionnaires were used. Statistical analysis was performed using the Statistica 10 software. Results. The majority of patients (99.2 %) are informed about the necessity of PSA level monitoring. However, 36.8 % did not know threshold PSA levels, 18.7 % did not undergo examination in a timely manner, and 4.3 % weren’t informed on the timeframes of monitoring. BR was diagnosed in 11.43 % of patients. Among them, in 16.2 % clinical recurrence was detected due to late BR diagnostics and belated visit to an oncologist. However, no statistically significant correlation between cognizance level, examination regularity with development of clinical recurrence was found (p 0.05). In 39.3 % of cases, treatment of prostate cancer due to diagnosed BR was delayed. Conclusion. Despite high general cognizance, significant deficit of practical knowledge and low adherence to regular monitoring were observed. To decrease the number of clinical recurrences developed due to delayed start of treatment after BR, comprehensive approach is necessary consisting of patient briefing and optimization of control methods at the medical facilities performing outpatient observation.

  • Open Access

    Study of circulating regulatory T cells in solid cancers

    by T. Yu. Mushkarina, Е. Г. Кузьмина, V. A. Biryukov, G. V. Afonin, L. Yu. Grivtsova, Л. Ю. Гривцова

    Regulatory T cells (Tregs) play a key role in maintaining peripheral immune tolerance. Disorders in their functioning are associated with the development of autoimmune, allergic and oncological diseases. The aim of the study was to evaluate the involvement of circulating Treg cells in the development of solid malignancies. Materials and methods. The level of Treg cells (CD 45 + CD 4 + CD 25 + CD 127 -/low ) in the peripheral blood of patients with cervical cancer (CC, n=10), prostate cancer (PC, n=23) and lung cancer (LC, n=10) was determined by flow cytofluorometry. The control group consisted of 40 healthy donors. The Mann-Whitney U-test was used to compare the indicators of the groups. Results . The study showed an increased level of circulating Treg cells in patients with CC, PC and LC compared with the control group (pConclusion . The data obtained confirm the universal role of Treg cells in the development and progression of solid tumors, which indicates the promise of immunomodulatory approaches aimed at regulating the activity of these cells.

  • Open Access

    Side effects and complications of high dose-rate brachytherapy: literature review and our own observations

    by E. O. Shchukina, V. A. Biryukov, O. B. Karyakin, S. А. Ivanov

    Background. Among malignant tumors in men in Russia, prostate cancer is the most common comprising 17 %. Despite the high effectiveness of radiotherapy for prostate cancer in about 20 % of patients, radiation damage of the pelvic organs develops affecting bladder, rectum, and intrapelvic cellular tissue.Aim. To evaluate early and late complications of high dose-rate brachytherapy.Materials and methods. Literature review was performed, and our own results of treatment of 276 patients using high dose-rate brachytherapy as monotherapy with different fractionation regimens: 19 Gy per 1 fraction and 15 Gy per 2 fractions were analyzed.Results. High dose-rate brachytherapy as monotherapy is associated with low complication rate. There were no statistically significant differences between singleand two-fraction regimens. Evaluation of complication severity per the RTOG (Radiation Therapy Oncology Group) classification did not show complication severity above grade III. Early complications were diagnosed in 1.1 %, late in 3.3 % of cases. Between the treatment and comparison groups, no statistically significant differences in the frequency of urinary system organ symptoms per the IPSS (International Prostate Symptom Score) questionnaire were registered. Mean score per the IPSS prior to treatment was 4.0 (3.0–6.0) in the treatment group and 4.0 (3.0–8.5) in the comparison group. Mean follow-up duration in the treatment group was 65.0 (60.0–70.0) months, in the comparison group – 55.0 (49.5–65.0) months. After the treatment, mean IPSS score was 5.0 (4.0–5.0) in the treatment group and 5.0 (3.0–7.0) in the comparison group.Conclusion. High dose-rate brachytherapy as monotherapy and in combination with external beam therapy is a safe and effective treatment method in prostate cancer. Serious and late complications are rare, however toxic effects of severity grades I or II can develop. Careful patient selection for brachytherapy, therapy planning methods, as well as active management of early and late toxicity by a multidisciplinary team with knowledge and experience in treatment of side effects of radiotherapy can help optimize treatment with high dose-rate brachytherapy.

  • Open Access

    High-dose-rate brachytherapy as monotherapy in patients with localized prostate cancer.

    by E.O. Shchukina, the Department of Radiation and Surgical Treatment of Urological Diseases with the Brachytherapy Group of Prostate Cancer of the Medical A. Tsyb Radiological Research Center – branch of the National Medical Research Center of Radiology of the Ministry of , V.A. Biryukov, O.B. Karyakin, S.A. Ivanov, Russia Obninsk

    Introduction. Prostate cancer is the second most common cancer among men. In Russia the number of patients with stage I-II prostate cancer increased from 47,7% in 2010 to 60,7% in 2021. One of the mai

  • Open Access

    Combined radiotherapy and hormone therapy in unfavorable intermediate risk prostate cancer

    by K S Makarova, Yu. V Gumenetskaya, V A Biryukov, T A Rodina, A B Galitsyna, E O Shchukina, O B Karyakin, S A Ivanov, A D Kaprin

    Background. Currently, the group of intermediate risk prostate cancer (PC) includes 2 subgroups - favorable and unfavorable intermediate risk according to the National Comprehensive Cancer Network (NCCN) classification. The optimal scope of therapy is not defined for the unfavorable intermediate risk subgroup. In particular, the need for and duration of hormone therapy (HT) during combined radiotherapy (CRT) have not yet been determined.Aim. To perform a comparative analysis of the efficacy and toxicity of CRT in patients with unfavorable intermediate risk treated with and without HT.Materials and methods. Eighty-four (84) patients with unfavorable intermediate risk PC were treated with CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center between May 2016 and December 2020. Patients were divided into two groups: external beam radiation therapy + brachytherapy (n = 40) and external beam radiation therapy + brachytherapy + HT (n = 44). Conformal external beam radiation therapy was delivered with conventional fractionation to a total dose of 44-46 Gy and the 192Ir high-dose rate brachytherapy was delivered with a single fraction of 15 Gy. Median duration of HT consisting of gonadotropin-releasing hormone agonist was 6 months. Median age was 65.2 years (range: 49-80 years). Median follow-up was 58.1 months (range: 18.6-83.7 months).Results. With a median follow-up of 4.8 years, progression-free survival was 95 % and 97.6 % in the external beam radiation therapy + brachytherapy group and external beam radiation therapy + brachytherapy + HT group, respectively (p = 0.578). The break between treatment stages of more than 28 days was associated with a statistically significant increase in the risk of PC recurrence (p = 0.007). Overall survival for the external beam radiation therapy + brachytherapy group versus external beam radiation therapy + brachytherapy + HT group was 97.5 and 93.2 % (p = 0.376), respectively.Late genitourinary toxicity was grade I in 8 (9.5 %) patients and grade II in 1 (1.2 %) patient. Urethral stricture developed in 3 (3.6 %) patients. Late gastrointestinal toxicity was grade I in 7 (8.3 %) patients and grade II in 1 (1.2 %) patient. There were no statistically significant differences in the incidence of late complications between groups with and without HT. There was a statistically significant (p = 0.049) effect of prostate volume on the incidence of late radiation proctitis.Conclusion. There were no statistically significant differences in progression-free survival and overall survival in patients with unfavorable intermediate risk PC who received external beam radiation therapy + brachytherapy with or without HT. The incidence and severity of adverse events were acceptable and allowed patients with PC to maintain high quality of life.


  • Open Access

    Radioligand therapy with 177Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy

    by V. V. Krylov, N. S. Legkodimova, T. Yu. Kochetova, V. M. Petriev, M. A. Sigov, V. K. Tishchenko, A. I. Pronin, A. Yu. Shurinov, K. M. Petrosyan, O. N. Spichenkova, et al.

    INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article.OBJECTIVE: The pharmacokinetics, safety and tolerability of radiopharmaceutical were studied. Tolerability of increasing activities — 5.0, 7.5 and 10.0 GBq was investigated.MATERIALS AND METHODS: The study included 12 patients with metastatic castration-resistant prostate cancer, who progressed after previous treatment. The first 4 patients was treated by 5 GBq of 177Lu DOTA-PSMA, the next 4 patients of the second group was treated by 7.5 GBq, and the 4 patients of the third group was treated by 10 GBq. Radiopharmacokinetics was studied by whole-body scintigraphy, SPECT/CT, blood and urine radiometry. The radiation-absorbed dose (RAD) of metastases and organs at risk was studied by clinical dosimetry. Safety assessment also was studied by hematological status. All patients was taken a complete blood count, a biochemical blood test before course of therapy treatable and during the case study.RESULTS: Study data showed high accumulation of 177Lu-DOTA-PSMA the in pathological focus, the distribution in the body conformed to the previous data of PET/CT study. Blood radiometry showed that 177Lu-DOTA-PSMA rapidly excreted from the bloodstream (during the first hours after injection). Urine radiometry showed that, more than half of the injected dose was excreted during 2 days (from 34.4% to 88.8%).DISCUSSION: During the study was solicited increasing of pain syndrome, dry mouth. Most patients had moderate myelosuppression. Changes in hematological parameters had a transistor character, the adverse event resolved without consequences in 5 week. 4th grade of NCI CTCAE hematological toxicity criteria wasn’t identified. Serious adverse events weren’t identified too.CONCLUSIONS: Radiopharmaceutical demonstrated high affinity for tumor tissue and safety in the clinical use. Data, which demonstrating a high potential anti-tumor efficacy of radiopharmaceutical, were obtained. Dosimetric studies showed radiation safety of work with radiopharmaceutical for the personnel.


  • Assessment of toxicity of elective pelvic lymph node irradiation in patients with high-risk prostate cancer

    by T.A. Kireeva, Yu.V. Gumenetskaya, V.A. Biryukov, A.A. Obukhov, K.S. Makarova, I.A. Strikanova, S.O. Dzhabrailova, O.G. Lepilina, S.A. Ivanov, A.D. Kaprin

    Применение сочетанной лучевой терапии (СЛТ) позволяет повысить эффективность лечения рака предстательной железы (РПЖ) у больных высокого онкологического риска. Остается неясным, имеет ли какое-либо преимущество включение в область облучения регионарных лимфоколлекторов с профилактической целью, поскольку эскалация дозы, как и увеличение объема облучения, сопряжены с высоким риском развития лучевых осложнений, которые, как известно, негативно влияют на качество жизни пациентов. ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение влияния профилактического облучения лимфатических узлов малого таза на непосредственные результаты лечения, а также на качество жизни больных РПЖ высокого онкологического риска. МАТЕРИАЛ И МЕТОДЫ В период с ноября 2019 по январь 2021 г. в МРНЦ им. А.Ф. Цыба 60 больным РПЖ в объеме гормонолучевого лечения выполнена СЛТ. Пациенты были рандомизированы в две группы: с облучением регионарных лимфоколлекторов (n=32) и без их облучения (n=28). На первом этапе лечения проведен курс конформной дистанционной лучевой терапии до суммарной очаговой дозы 46 Гр. На втором этапе однократно выполнен сеанс высокомощностной брахитерапии (192Ir) в разовой очаговой дозе 15 Гр. РЕЗУЛЬТАТЫ Развитие острого лучевого цистита 1-й степени тяжести отмечено у 11 (34,4%) больных 1-й группы и у 12 (42,9%) пациентов 2-й (p=0,83). Во 2-й группе у 1 (3,6%) пациента отмечен острый лучевой цистит 2-й степени тяжести. Острый лучевой ректит 1-й степени тяжести наблюдался у 13 (40,6%) пациентов 1-й группы и у 3 (10,7%) 2-й (p=0,01) группы. ЗАКЛЮЧЕНИЕ Предварительный анализ исследования показал увеличение частоты развития лучевых реакций в группе пациентов с профилактическим облучением регионарных лимфоколлекторов.


  • Open Access

    Combinatorial radiation therapy for prostate cancer with seminal vesicle invasion

    by K. S. Makarova, Yu. V. Gumenetskaya, V. A. Biryukov, I. A. Strikanova, T. A. Kireeva, O. G. Lepilina, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin, Ю. В. Гуменецкая

    Background. It seems advisable to investigate the feasibility of radiation therapy combined with hormone therapy to treat locally advanced prostate cancer. Combination of two ways to deliver ionizing radiation doses enables us to elevate a total tumor dose and to reduce radiation exposure to critical organs. However, the feasibility of combinatorial radiation therapy (CRT) in prostate cancer patients with seminal vesicle invasion remains insufficiently investigated. The number of studies focusing on this problem is still extremely small.Objective of this study is to evaluate the efficacy and toxicity of radiation therapy combined with hormone therapy for prostate cancer with seminal vesicle invasion.Materials and methods. From April 2016 to April 2020, 52 patients with prostate cancer (cT3bN0) received CRT at the clinic of the A.F. Tsyb Medical Radiological Research Center. The median patient follow-up was 29.7 months (from 11.9 to 58.4 months). The mean age of patients was 65.7 years. The initial mean level of PSA was 28.7 ng/ml. Fifty (96.2 %) patients were given radiation therapy together with hormone therapy.Results. The tolerability of CRT appeared satisfactory. Grade I acute radiation-induced reactions of the urinary tract occurred in 13 (25 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I acute radiation-induced reactions of the gastrointestinal tract occurred in 11 (21.5 %) patients; grade II ones - in 1 (1.9 %) patient. Grade I late complications of the urinary tract were noted in 4 (7.7 %) patients; grade II ones - in 2 (3.8 %) patients. Grade I late complications of the gastrointestinal tract were noted in 2 (3.8 %) patients; grade II ones - in 3 (5.8 %) patients.The three-year cancer-specific survival rate was 97 %; the overall survival rate was 83 %. Eight (15.4 %) patients showed prostate cancer progression. Five (9.6 %) patients experienced cancer recurrence in the form of distant bone metastases. In 1 (1.9 %) patient, disease recurrence was associated with involvement of regional lymphatic collectors and distant inguinal lymph node metastases. Local recurrence was noted in 1 (1.9 %) patient. One (1.9 %) patient developed loco-regional recurrence with distant metastasis to bones. The three-year recurrence-free survival rate was 75.6 %.Conclusion. Our study demonstrates that CRT is highly effective in prostate cancer (cT3bN0) treatment while having an acceptable level of complications.